EP3755312A4 - Dosage forms and methods for enantiomerically enriched or pure bupropion - Google Patents

Dosage forms and methods for enantiomerically enriched or pure bupropion Download PDF

Info

Publication number
EP3755312A4
EP3755312A4 EP19756920.5A EP19756920A EP3755312A4 EP 3755312 A4 EP3755312 A4 EP 3755312A4 EP 19756920 A EP19756920 A EP 19756920A EP 3755312 A4 EP3755312 A4 EP 3755312A4
Authority
EP
European Patent Office
Prior art keywords
methods
dosage forms
enantiomerically enriched
pure bupropion
bupropion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19756920.5A
Other languages
German (de)
French (fr)
Other versions
EP3755312A1 (en
Inventor
Herriot TABUTEAU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axsome Therapeutics Inc
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of EP3755312A1 publication Critical patent/EP3755312A1/en
Publication of EP3755312A4 publication Critical patent/EP3755312A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP19756920.5A 2018-02-23 2019-02-25 Dosage forms and methods for enantiomerically enriched or pure bupropion Pending EP3755312A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862634718P 2018-02-23 2018-02-23
US201962794469P 2019-01-18 2019-01-18
US201962809480P 2019-02-22 2019-02-22
PCT/US2019/019445 WO2019165379A1 (en) 2018-02-23 2019-02-25 Dosage forms and methods for enantiomerically enriched or pure bupropion

Publications (2)

Publication Number Publication Date
EP3755312A1 EP3755312A1 (en) 2020-12-30
EP3755312A4 true EP3755312A4 (en) 2022-03-16

Family

ID=67688503

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19756920.5A Pending EP3755312A4 (en) 2018-02-23 2019-02-25 Dosage forms and methods for enantiomerically enriched or pure bupropion

Country Status (18)

Country Link
EP (1) EP3755312A4 (en)
JP (3) JP2021513998A (en)
KR (3) KR20240091043A (en)
CN (1) CN112087999A (en)
AU (3) AU2019223187B2 (en)
BR (1) BR112020017179A2 (en)
CA (1) CA3092076A1 (en)
CL (1) CL2020002166A1 (en)
CR (1) CR20200415A (en)
EC (1) ECSP20060179A (en)
IL (2) IL313368A (en)
MA (1) MA51914A (en)
MX (2) MX2020008704A (en)
NI (1) NI202000056A (en)
NZ (1) NZ767378A (en)
PE (1) PE20211752A1 (en)
SG (1) SG11202008056SA (en)
WO (1) WO2019165379A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11660274B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660273B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11291639B2 (en) 2018-09-20 2022-04-05 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
BR112022005045A2 (en) * 2019-09-20 2022-07-05 Axsome Therapeutics Inc DOSAGE FORM, USE AND KIT OF(S)-BUPROPION THAT IS AT LEAST 95% ENANTIOMERICALLY PURE

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9474731B1 (en) * 2013-11-05 2016-10-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2318960A1 (en) * 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (+)-bupropion
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
EP1575565B1 (en) * 2003-08-08 2010-01-06 Biovail Laboratories International Srl Modified-release tablet of bupropion hydrochloride
WO2012118562A1 (en) * 2011-03-02 2012-09-07 Rhine Pharmaceuticals, Llc Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations
US9198905B2 (en) * 2013-11-05 2015-12-01 Antecip Bioventures Ii Llc Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
US10080727B2 (en) * 2013-11-05 2018-09-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US9732031B2 (en) * 2013-12-20 2017-08-15 Deuterx, Llc Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9474731B1 (en) * 2013-11-05 2016-10-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects

Also Published As

Publication number Publication date
NI202000056A (en) 2021-01-11
BR112020017179A2 (en) 2020-12-22
IL313368A (en) 2024-08-01
IL276871B1 (en) 2024-07-01
EP3755312A1 (en) 2020-12-30
WO2019165379A1 (en) 2019-08-29
KR20210003091A (en) 2021-01-11
AU2024205858A1 (en) 2024-09-05
CL2020002166A1 (en) 2020-10-23
MX2023009281A (en) 2023-08-17
MA51914A (en) 2020-12-30
KR20230075531A (en) 2023-05-31
CN112087999A (en) 2020-12-15
NZ767378A (en) 2024-03-22
IL276871A (en) 2020-10-29
SG11202008056SA (en) 2020-09-29
ECSP20060179A (en) 2020-12-31
AU2019223187A1 (en) 2020-09-17
KR20240091043A (en) 2024-06-21
JP2021513998A (en) 2021-06-03
CA3092076A1 (en) 2019-08-29
AU2019223187B2 (en) 2022-07-28
JP2024075655A (en) 2024-06-04
MX2020008704A (en) 2020-12-07
AU2022204521B2 (en) 2024-09-05
PE20211752A1 (en) 2021-09-06
JP2022153638A (en) 2022-10-12
CR20200415A (en) 2021-02-03
AU2022204521A1 (en) 2022-07-21

Similar Documents

Publication Publication Date Title
EP3869985A4 (en) Composition and method for treating the lungs
EP3733715A4 (en) Triabody, preparation method and use thereof
EP3752231A4 (en) Method and inhaler for providing two or more substances by inhalation
EP3665181A4 (en) Compositions and methods for decolonizing antibotic-resistant bacteria in the gut
EP3755312A4 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
EP3324975A4 (en) Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof
EP3801552A4 (en) Composition and method for inhalation
EP3507977A4 (en) Systems and methods for encoding and playing back 360 view video content
IL287905A (en) Pharmaceutical composition containing brexanolone, ganaxolone, or zuranolone, and use thereof
EP3559133A4 (en) A coating composition system, the preparation method, and the use thereof
EP3429598A4 (en) Compositions and methods for the treatment of a beta-catenin-associated disease or disorder
EP3406602A4 (en) 1-sulfonamido-4-aryloxy compound, and preparation method and medicinal application thereof
EP3351549A4 (en) Composition rich in single isomer nuc-1031 and preparation method and use thereof
EP3275454A4 (en) Pharmaceutical composition containing silybin, ve and l-carnitine
EP3593785A4 (en) Dental composition and preparation method therefor
EP3760191A4 (en) Pharmaceutical composition and preparation method therefor and use thereof
EP3456711A4 (en) Caspase inhibitor and pharmaceutical composition, use and therapeutic method thereof
EP3760616A4 (en) 4-methyldihydropyrimidinone compound and medicinal use thereof
IL282999A (en) 1,3,4-oxadiazolone compound and pharmaceutical
EP4076485A4 (en) Extracts enriched with polyphenolic compounds and related methods
EP4056683A4 (en) Brain organoid and use thereof
EP3813842A4 (en) Pharmaceutical composition and preparation method thereof
EP3765081A4 (en) Antimicrobial photosensitizer composition and method
EP3773541A4 (en) Isotopically modified composition and therapeutic uses thereof
EP3244884A4 (en) Intravenous baclofen formulations and treatment methods

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200921

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: TABUTEAU, HERRIOT

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40041795

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20220216

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101ALI20220210BHEP

Ipc: A61P 25/30 20060101ALI20220210BHEP

Ipc: A61P 25/28 20060101ALI20220210BHEP

Ipc: A61P 25/24 20060101ALI20220210BHEP

Ipc: A61P 25/18 20060101ALI20220210BHEP

Ipc: A61P 25/00 20060101ALI20220210BHEP

Ipc: A61K 31/485 20060101ALI20220210BHEP

Ipc: A61K 31/137 20060101AFI20220210BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230306

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AXSOME THERAPEUTICS, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS